Objectives: Oxaliplatin immune-induced syndrome (OIIS) was recently recognized as an uncommon complication of oxaliplatin therapy.
Methods: We report an exceptionally OIIS after pressurized intraperitoneal aerosol chemotherapy (PIPAC).
Results: Our patient developed a severe OIIS probably related to the intraperitoneal administration of oxaliplatin. Specific tests were performed and detected high-titer antibodies to oxaliplatin.
Conclusions: The OIIS is a rare. Physicians had to be aware of that clinical situation because it could be reversible, even in case of peritoneal advanced disease, and ICU treatment is justified.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9069496 | PMC |
| http://dx.doi.org/10.1515/pp-2021-0138 | DOI Listing |
Publication Analysis
Top Keywords
oxaliplatin immune-induced
8
immune-induced syndrome
8
pressurized intraperitoneal
8
intraperitoneal aerosol
8
aerosol chemotherapy
8
severe oxaliplatin
4
syndrome oxaliplatin-based
4
oxaliplatin-based pressurized
4
chemotherapy pipac
4
pipac objectives
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!